GW - Autism Spectrum Disorder Treatment
From Healthcare Professionals - Research & Trials - Therapeutic Areas
Many of the childhood-onset intractable epilepsy conditions within the expanded access program share considerable overlap with ASD and these conditions often fall within the orphan disease space. Initial clinical observations from treating physicians suggest a potential role for cannabinoids in addressing problems associated with ASD such as deficits in cognition, behavior, and communication.
-
Most popular related searches
Details
GW has evaluated the cannabinoids CBD and CBDV in both general and syndromic pre-clinical models of ASD yielding promising signals on cognitive and social functioning endpoints as well as repetitive behaviors.
At this time, GW’s clinical program in ASD is focused on the use of CBDV, which includes both open-label and investigator-led studies.
Customer reviews
No reviews were found for GW - Autism Spectrum Disorder Treatment. Be the first to review!